A Phase Ic Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-302168S Tablets in Overweight/Obese Subjects After Multiple Oral Administration.

A Phase Ic clinical trial is currently underway in China to evaluate the safety and effectiveness of DA-302168S tablets in overweight/obese individuals. The trial involves a 28-day period of continuous oral administration of the tablets and aims to assess any adverse events and analyze plasma samples for pharmacokinetics. The study is currently in the recruitment phase and plans to enroll 60 participants, with a completion date set for September 2025. Eligibility criteria include age, weight, body mass index, and stable weight in the months leading up to screening, while exclusion criteria include certain medical conditions. The primary contact for the study is Dr. Guang xin Dong. [Extracted from the article]